Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.49 |
| ▸ | PLD1 | Q13393 | 10/20 | 0.46 |
| ▸ | PLD2 | O14939 | 4/20 | 0.46 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779165 | 0.93 | NPC1L1 (0.51) | OPRK1NPC1L1OPRM1OPRD1OPRL1 | |
| SCHEMBL5783375 | 0.91 | CTSB (0.50) | CTSBCTSSCTSKOPRK1PLD1 | |
| SCHEMBL6481140 | 0.90 | OPRK1 (0.52) | CTSBCTSSCTSKOPRK1PLD1 | |
| SCHEMBL5782996 | 0.89 | CTSB (0.53) | CTSBCTSSCTSKOPRK1PLD1 | |
| SCHEMBL5780094 | 0.88 | CTSB (0.58) | CTSBCTSSCTSKOPRK1PLD1 | |
| SCHEMBL5781330 | 0.84 | NPC1L1 (0.44) | OPRK1NPC1L1OPRM1OPRD1OPRL1 | |
| SCHEMBL6475394 | 0.84 | NPC1L1 (0.44) | CTSBCTSSCTSKOPRK1NPC1L1 | |
| SCHEMBL5783140 | 0.83 | NPC1L1 (0.46) | OPRK1NPC1L1OPRM1OPRD1OPRL1 | |
| SCHEMBL5780139 | 0.83 | NPC1L1 (0.45) | OPRK1NPC1L1OPRM1OPRD1OPRL1 | |
| SCHEMBL5780117 | 0.83 | NPC1L1 (0.44) | OPRK1NPC1L1OPRM1OPRD1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919349-B2 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | TORAY INDUSTRIES, INC. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040087574-A1 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | TORAY INDUSTRIES INC. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1329451-A1 | SPIRO COMPOUNDS AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087574-A1 | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient | VCAM1, ICAM1, SELL | CTSB 2017/4885CTSS 2893/4885CTSK 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.